
ã³ããã¯ã¯ãã³ã¯ãããåŒãèµ·ããã®ãïŒçç©åŠææãæèŠãè¿°ã¹ã
å èšäºã¯ãã¡ããã/Click here to read the original article.
ããµãã¥ãŒã»ããå·ã¿ãã倧åŠçºéã»ååã»ååŠçç©åŠéšã®ã·ã£ãŒãããã»ã¯ãŒããŒã¯ããµãŒææã¯ãCOVID-19 mRNAã¯ã¯ãã³æ¥çš®ãšãããçµã³ã€ããå¯èœæ§ã®ãããçç©åŠçã«åŠ¥åœãª3ã€ã®ã¡ã«ããºã ã説æããŠããã
ãŸããçºçããŠããããã®ãã¿ãŒã³ã«ã€ããŠãèšåããŠããããããã¯å æé¢ä¿ã蚌æãããã®ã§ã¯ãªãããåãªãå¶ç¶ãšããŠçä»ããã¹ãã§ã¯ãªããšææããŠããã
ã¯ããã«
éåžžã«è°è«ãåŒã¶è©±é¡ã«è§Šããããããçç©åŠè ãå»ççå šäœã«ãšã£ãŠãè§ŠããŠã¯ãããªã話é¡ããšãªã£ããCOVID-19ã¯ã¯ãã³ãšãããšã®é¢é£æ§ã«ã€ããŠã ãç§ã®ç 究宀ã¯ããäºé²ãäžæ žãšãã䜿åœãæ ã£ãŠããããããã®é倧ãªåé¡ãç¡èŠããããšã¯è¯å¿ã«åããã
åœéçã«èåãªããçç©åŠè ã§ããååã®ã¯ãã£ã¯ã»ãšã«ãã€ãªå士ãšç§ãã9æã®ACIPïŒäºé²æ¥çš®è«®åå§å¡äŒïŒã«ãããCOVIDã¯ã¯ãã³äŒè°ã§è¿°ã¹ãããã«ãCOVID-19 mRNAã¯ã¯ãã³æ¥çš®ãšããçºçã®éã«æéçé¢é£æ§ãå ±åããè«æã¯50ä»¶è¿ãã«äžããŸããç«åŠç ç©¶ïŒã€ã¿ãªã¢ãšéåœã®å1ä»¶ïŒããæªæ¥çš®çŸ€ãšæ¯èŒããã¯ã¯ãã³æ¥çš®è ã«ãããããçºççã®äžæãå ±åããŠããïŒãã ãæ³šæç¹ããïŒãããããå ±åã¯å¢å åŸåã«ãããåŠè¡çã»ã¡ãã£ã¢ã»èŠå¶åœå±ã§äž»æµãšãªã£ãŠãããå³åº§ã«åŠå®ããã察å¿ã§ã¯ãªããäœãéèŠãªçŸè±¡ãèµ·ããŠããå¯èœæ§ãèªããæãæ¥ãŠããã
æ¬çš¿ã®ç®çã¯ãç§åŠçæ ¹æ ãè§£æããCOVID-19 mRNAã¯ã¯ãã³ãšçã®é¢é£æ§ã«é¢ãã劥åœãªçç©åŠçã¡ã«ããºã ãæŠèª¬ããããšã§ããããªãç·æ¥èª¿æ»ã®å¿ èŠæ§ã瀺ãããšã«ãããçµè«ãæ¥ãã®ã§ã¯ãªãããã®åé¡ã®éèŠæ§ãæç¢ºåããç§åŠçè°è«ã®æŽ»æ§åããããŠäœãããç ç©¶è³éããã®ç·æ¥ãã€æ¡å€§ããæžå¿µé åã«åããããããšãæåŸ ãããçŸç¶ã§ã¯ãç§åŠè ãå人çã»è·æ¥çãªå ±åŸ©ãæããã«ãã®åé¡ãç ç©¶ããããšã¯äžå¯èœãšãªã£ãŠããã
ç§ãã¡ãç¥ã£ãŠããããšãšç¥ããªãããš
çŸæç¹ã§ã¯ãmRNAã¯ã¯ãã³ãçãèªçºããçŽæ¥çãªå æã¡ã«ããºã ã瀺ãå ¬è¡šãããç ç©¶ã¯ååšããªããããããããã¯ãã®ãããªå æé¢ä¿ãååšããªãããšãæå³ããªããå®éãççºçãšã®æ¢ç¥ã®é¢é£æ§ãèæ ®ããã°ãå³å¯ãªç ç©¶ãšè©äŸ¡ã«å€ããçç©åŠçã«åŠ¥åœãªã¡ã«ããºã ãå°ãªããšãäžã€ååšããããããã¯ä»¥åã«ãå¥ã®æèã§è«ããããããã§ã¯ããããCOVID-19 mRNAã¯ã¯ãã³ã«ã©ã®ããã«é©çšãããå¯èœæ§ããããã説æããã
ã¡ã«ããºã 1ïŒã¹ãã€ã¯ã¿ã³ãã¯è³ªã®çç©åŠçç¹æ§ã«ãã现èå€ç°
æ£åžžçްèãç现èãžå€ç°ããéçšã§ã¯ã现è墿®ã»çåã»DNA修埩ãå¶åŸ¡ããè€æ°ã®å®å 𿩿§ãç Žå£ããããCOVID-19 mRNAã¯ã¯ãã³ã¯ãäœå ã®çްèã«SARS-CoV-2ã¹ãã€ã¯ã¿ã³ãã¯è³ªãé·æã«ãããïŒæ°æ¥ããæ°é±éãæ°ã¶æãããã«ã¯æ°å¹ŽïŒç£çãããããæç€ºããããšã§äœçšããããã®å€æ¥ã¹ãã€ã¯ã¿ã³ãã¯è³ªãå ç«å¿çãèªçºããã
å®éšå®€ç ç©¶ã§ã¯ãææã«ãããã®ã§ããã¯ã¯ãã³æ¥çš®ã«ãããã®ã§ãããã¹ãã€ã¯ã¿ã³ãã¯è³ªãçç©åŠç掻æ§ãæããããšãå ±åãããŠãããããã¯çްèåšæãè «çæå¶æ©èœãDNAæå·ä¿®åŸ©çµè·¯ããã³æ©æ§ã調ç¯ãã现èå çµè·¯ãšçžäºäœçšããããããã£ãŠçè«äžãã¹ãã€ã¯ã¿ã³ãã¯è³ªãšãããã®çµè·¯ãšã®çžäºäœçšã¯çްèå€ç°ã«å¯äžãåŸãââãã ãããã¯COVID-19ææèªäœã«ãèšããããšã§ããããããéãã¯ãèªç¶ææãšæ¯èŒããã¯ã¯ãã³æ¥çš®åŸã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªç£çæç¶æéã«ãããããã¯ãŸããè€æ°åã®COVIDææãã¯ã¯ãã³ç£çã®äººå·¥ã¹ãã€ã¯ã¿ã³ãã¯è³ªãšçç©åŠçã«åçãåŠããšããéèŠãªçåãæèµ·ããã
mRNAã«ãã£ãŠç£çãããã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ãã¯ã¯ãã³æ¥çš®åŸãããæ°æ¥ããæ°é±éãæ°ã¶æãããã«ã¯æ°å¹Žã«ãããã£ãŠæç¶ããå¯èœæ§ããããããããçºççãäœå ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªçºçŸïŒãŸãã¯æç¶ïŒãšçžé¢ãããã©ããããŸãè «çå ã«ååšãããã©ãããèªèããããšãéèŠã§ãããæè¿ã®çäŸç ç©¶ã§ã¯ã転移æ§ä¹³ããã«ãããŠã¹ãã€ã¯ã¿ã³ãã¯è³ªãçºçŸããŠãã蚌æ ã瀺ãããããããã£ãŠãCOVIDã¯ã¯ãã³ãšçã®é¢ä¿ãèããäžã§ã现èåšæãDNAæå·å¿ççµè·¯ãç Žå£ããçç©åŠç掻æ§ãæããç©è³ªãžã®æ ¢æ§çãªæé²ãèæ ®ããããšã¯æ¥µããŠéèŠã§ããããã®å¯èœæ§ãå®å šã«åŠå®ããããšã¯æ æ ¢ãšèšããããçŸæç¹ã§ã¯ããããã«ã€ããŠæ±ºå®çãªçµè«ãäžãã«ã¯ããŒã¿ãäžååã§ããããã®ãããªããŒã¿ãååšããªã以äžããã®ã¡ã«ããºã ãå®å šã«åŠå®ããããšã¯ã§ããªãã
ã¡ã«ããºã 2ïŒæ®çDNAæ±æç©è³ªã«ããã²ãã çµ±åãšéºäŒåçºçŸã®ç°åžž
çŸåšãè£œé æ¥è ãFDAããªãã³ã«NIHã®ç ç©¶æãå«ãä»ã®æ©é¢ããmRNAã¯ã¯ãã³ã«DNAäžçŽç©ãæ®çããŠããããšãèªããŠããã
ã¯ã¯ãã³è£œå€äžã®å«æéã¯æå®³æ§ãåãŒãã«ã¯å°ãªããããšäž»åŒµããè ãå€ãããäºå®ã¯ä»¥äžã®éãã§ããïŒ
1ããããã®æçã¯ååšããŠããïŒ
2ããããã¯DNAã现èå ããã³æ žãžå¹ççã«å°å ¥ããè質ããç²åã§éã°ããïŒãããŠã
3ããããã®æçã®ãµã€ãºã¯ãç¹ã«çްèãåè£ãèªç¶ãªDNA修埩ãåããŠããéã«ã容æã«ã²ãã ãžçµã¿èŸŒãŸããå¯èœæ§ãããã
ãããã®äžçŽç©ã®éã现èãžã®ãã©ã³ã¹ãã§ã¯ã·ã§ã³ã«äžååã§ãããçµã¿èŸŒãŸããªãããšãå®èšŒããç ç©¶ã¯è¡ãããŠããªãããããããèµ·ããåŸããå®éã«èµ·ããŠããªããšãã䞻匵ã¯çŸæç¹ã§ã¯å®å šãªæšæž¬ã«éããªããèšãæããã°ããããã®äžçŽç©ã现èå ãžäŸµå ¥ãããDNAãžçµã¿èŸŒãŸãããããã«ã¯å°ãªãããããšã瀺ãç ç©¶ã¯æªã ååšããªãã
ãã¡ã€ã¶ãŒè£œã¯ã¯ãã³ã«ãããŠã¯ãäžçŽç©ã®äžéšããŠã€ã«ã¹æ§èª¿ç¯å åã§ããDNAé åãå«ãã§ãããå®çŸ©äžãããã¯éºäŒåçºçŸã«åœ±é¿ãåãŒããããã«æ°ããªç¥èŠã«ããã°ããã¡ã€ã¶ãŒè£œã¯ã¯ãã³ã«ã¯ã¡ãã«åãããDNAãå«ãŸããŠãããããã¯çްèå ã®cGAS-STINGçµè·¯ãåºæ¿ããå¯èœæ§ãããããããã£ãŠãå°ãªããšããã¡ã€ã¶ãŒã¯ã¯ãã³ã«ãããŠã¯ããããã®DNAäžçŽç©ã¯çµã¿èŸŒãŸããå¯èœæ§ã ãã§ãªããåºç¯ãªåœ±é¿ãåãŒãæœåšæ§ãæã€ã
誀ã£ãã²ãã ç°å¢äžã§ã®DNAçµã¿èŸŒã¿ã¯ãç¹ã«cGAS-STINGçµè·¯ã®æç¶ç掻æ§åãSV40ããã¢ãŒã¿ãŒéºäŒå調ç¯ãšçžãŸã£ãŠãéºäŒåçºçŸã®ç°åžžèª¿ç¯ãåŒãèµ·ããã现èå€ç°ã«å¯äžããå¯èœæ§ãããã
ååçç©åŠã®åºç€ã¯ãè質ããç²åãçšããŠDNAã现èå ã«å°å ¥ããæè¡ã«ããããã®éçšã§äžå¯é¿çã«çããå¯ç£ç©ãšããŠãDNAã®äžéšãçµã¿èŸŒãŸãããçµã¿èŸŒãŸããDNAã¯éºäŒåçºçŸãå€åãããéºäŒåæ©èœãç Žå£ããèœåãæã€ãmRNAã¯ã¯ãã³äžã®DNAäžçŽç©ã§ã¯ãããèµ·ãããªããšä»®å®ããã®ã¯èª€è§£ãæããmRNAã¯ã¯ãã³è£œå€äžã®DNAäžçŽç©ã现èãšæ¥è§Šããéã®éåœïŒin vitro ãŸã㯠in vivo ã«ãããŠïŒã¯ãåã«æªç¥ãªã®ã§ããããããèµ·ããåŸãªãããããã¯ã¯ã¯ãã³æ¥çš®åŸã«çºçããªããšããããŒã¿ã¯ååšããªãã
è質ããç²åã«ãã现èãžã®DNAå°å ¥ã¯DNAãã©ã³ã¹ãã§ã¯ã·ã§ã³ã«ä»ãªããªããšãã»ãŒå šãŠã®ååçç©åŠè ãåæããã ããããããã£ãŠãã®ã¡ã«ããºã ïŒããã³SV40ããã¢ãŒã¿ãŒé åã®çµã¿èŸŒã¿ããã©ã³ã¹ãã§ã¯ããããã¡ãã«åDNAã®åœ±é¿ïŒã«ãããçè«äžãDNAæ±æç©è³ªãé©åãªæ¡ä»¶äžã§çްèå€ç°ãèªçºãŸãã¯ä¿é²ããå¯èœæ§ãçãããæªè§£æ±ºã®åé¡ã¯ããããã©ã®çšåºŠã®é »åºŠã§çºçãããããããŠå®éã«çºçãããã©ããã§ãããçŸæç¹ã§ã¯ãã®çãã¯äžæã§ãããåè¿°ã®éãããã®çŸè±¡ã®çºçæç¡ãé »åºŠãç ç©¶ããŠããè ã¯ããªãããããã£ãŠãçŸæç¹ã§ã¯ãããã®ã¡ã«ããºã ãæ¯æããçµè«ãåŠå®ããçµè«ãå°ãåºããªãã
ã¡ã«ããºã 3ïŒå ç«èª¿ç¯ç°åžžïŒæãæåãªé¢é£æ§
ã¯ã¯ãã³æ¥çš®ãšçã®é¢é£æ§ã説æããæã劥åœãªã¡ã«ããºã ãç¹ã«æéçé¢é£æ§ã«é¢ããŠã¯ãå ç«ç³»ãé¢äžããŠãããè€æ°ã®æ»èªä»ãç ç©¶ããmRNAã¯ã¯ãã³ã®å埩æ¥çš®åŸã®å ç«å€åãå ±åããŠãããããã«ã¯ççæ§ãµã€ãã«ã€ã³ã®å¢å ãT现èã®æ¶èãIgG4æäœç£çã®äžæãäžéæ§ã®å ç«æå¶ãå«ãŸããã
å ç«ç³»ã¯çã«å¯ŸããéèŠãªã²ãŒãããŒããŒãšããŠæ©èœããå€ç°çްèãé²è¡ããåã«èå¥ã»æé€ãããäžæ¹ã§ãç¹ã«æ ¢æ§åããççãšãã圢æ ã§ã¯ã匷åãªçºçå åãçä¿é²å åãšããŠäœçšããå¯èœæ§ãããããããã£ãŠãå ç«ã·ã¹ãã ãäžæçã«æ©èœäžå šã«é¥ã£ãã調ç¯ç°åžžãèµ·ããããããããã¯éå°åå¿ãããããå Žåãå ç«ç£èŠæ©èœã®å€±æãšæ ¢æ§ççã®çµã¿åããã¯ãæ¢åã®ç°åžžçްèã®å¢æ®ã蚱容ããã ãã§ãªããå®éã«ããããå®å šãªè «çæ§å€ç°ãžãšä¿é²ããå¯èœæ§ããããããã¯è «ç圢æã®ä¿é²ãããã«ã¯å éã«ã€ãªããããããŸã§ã«å ±åãããŠããæéççªå ã§å®¹æã«èгå¯ããããã
ã¿ã€ãã³ã°ãšçã®çºç
ã»ãšãã©ã®åºåœ¢è «çã¯çºçãŸã§ã«æ°å¹ŽãèŠããããããã£ãŠãã¯ã¯ãã³æ¥çš®åŸ6ïœ12ã«æä»¥å ã«çºçããããïŒæ°é±éããæ°ã«æã§åææªæ§åããé²è¡ããç¹å®ã®ãªã³ãè «ãé€ãïŒã¯ãã¡ã«ããºã 1ãŸãã¯2ãä»ããmRNAã¯ã¯ãã³ã«ããèªçºèŠå ã«èµ·å ããå¯èœæ§ã¯äœãã
ããããªãããããšãCOVID-19 mRNAã¯ã¯ãã³ãçºçèŠå ã§ãªãã£ããšããŠããæ¢åã®åçç¶æ ãŸãã¯æœåšæ§ç现èïŒæ¢ã«éºäŒçã«äžå®å®ã§å®å šãªè «çåãžã®è»¢æãå·®ãè¿«ã£ãŠããç¶æ ïŒããã¹ãã€ã¯ã¿ã³ãã¯è³ªã®æå³ãããäœçšãçšãªDNAçµã¿èŸŒã¿äºè±¡ã«ãã£ãŠä¿é²ãããå¯èœæ§ã¯äŸç¶ãšããŠèãããããããã«ãå ç«ç£èŠã«ãã£ãŠæå¶ãããŠããäŒç ç¶æ ãŸãã¯åŸ®å°ãªçã¯ãå ç«èª¿ç¯ç°åžžãéããŠè§£æŸãŸãã¯ä¿é²ãããå¯èœæ§ãããïŒã¡ã«ããºã 3ïŒã
泚ç®ãã¹ããã¿ãŒã³
è€æ°ã®ç ç©¶ã«ãããmRNAã¯ã¯ãã³æ¥çš®ã®å埩åŸã«å ç«æ©èœã«æž¬å®å¯èœãªå€åãçããããšãå ±åãããŠãããããã«ã¯ççãèªå·±å ç«ãããã³ç²åŸæ§æ©èœæ§å ç«äžå šã®äžåœ¢æ ãå«ãŸããããããã®å€åã¯é·æCOVIDã§ã確èªãããŠãããããã¯ã¯ãã³æ¥çš®è ãšæªæ¥çš®è éããªãã³ã«é·æCOVIDã®ã¯ã¯ãã³æ¥çš®è ãšæªæ¥çš®è éã§ããŒã¿åŸåãšãã¿ãŒã³ãåæããããšãéèŠãšãªãã
å ç«äžå šã¯ãã°ãã°æ ¢æ§ççã䌎ããããäž¡è ã¯è «çç£èŠæ©èœãšè «ç蚱容æ§ã«çŽæ¥çãªåœ±é¿ãåãŒãããããã£ãŠãä»ã®åŸå€©æ§å ç«äžå šçäŸïŒäŸïŒHIVææè ãèåšç§»æ€å容è ïŒã§èгå¯ãããäºæž¬å¯èœãªççºçãã¿ãŒã³ã«åºã¥ããäºæž¬ãããå åã芳å¯ãããå¯èœæ§ãããããããã®ãããé§åããã¡ã«ããºã ã¯ç¢ºç«ãããŠãããããçç©åŠè ã®éã§åºãèªèãããŠããã
ãªã³ãè «
æåã«æãé¡èã«èгå¯ãããã®ã¯ããªã³ãç³»æªæ§è «çãç¹ã«éããžãã³ãªã³ãè «ïŒNHLïŒãT现èãªã³ãè «ãããŒãããæ§ãªã³ãè «ãã³ãŸãæ§å€§çްèåB现èãªã³ãè «ïŒDLBCLïŒãªã©ã®äŸµæ»æ§B现èãªã³ãè «ã®å¢å ã§ããããããã®ããã¯å ç«å¶åŸ¡æ©æ§ããã³EBVãšãã¹ã¿ã€ã³ã»ããŒãŠã€ã«ã¹ïŒœçºçãšå¯æ¥ã«é¢é£ããŠãããå ç«ã¹ãã¬ã¹ãæ¶èç¶æ äžã§ã¯ãæœäŒEBVææãæã€B现èãå¶åŸ¡ãéããã¯ããŒã³å¢æ®ãèµ·ãããå®å šãªåœ¢è³ªè»¢æã«å¿ èŠãªè¿œå ã®ã²ãã å€ç°ãç²åŸããå¯èœæ§ãããã
å ç«äžå šæ£è ã§ã¯ããããããªã³ãè «ã¯å ç«æ©èœé害çºçåŸæ°ã¶æä»¥å ã«çŸããããšãå€ãããããã£ãŠãå埩mRNAã¯ã¯ãã³æ¥çš®ãæç¶çãªå ç«æ¹ä¹±åŸã®åæ§ã®æéçåæ ã¯ãç«åŠçãªç²Ÿæ»ãèŠããã
ç¹çãã¹ãã¯ãå ¬è¡šãããçäŸå ±åã«ãããŠã¯ã¯ãã³æ¥çš®åŸã®ãªã³ãè «ãé床ã«å€ãèŠãããç¹ã§ãããããã«ã¯æ°èŠçºçäŸãšå¯è§£åŸã®æ¥éãªåçºäŸã®äž¡æ¹ãå«ãŸããããããã®èгå¯çµæãå¶ç¶ããå ±åãã€ã¢ã¹ãããããã¯çã®å ç«é害ãã瀺ããã¯äžæã§ããããããããã®ãã¿ãŒã³èªäœã¯ãå ç«ç£èŠãæ©èœäžå šã«é¥ã£ãå Žåã«äºæ³ãããçç©åŠçã¡ã«ããºã ãšæŽåããŠããã
ãŠã€ã«ã¹é¢é£ãã
次ã«å¢å ãäºæ³ãããããã«ããŽãªãŒã«ã¯ããŠã€ã«ã¹æ§ç å ã®ãããå«ãŸããããããã¯å ç«ç£èŠã®å€±æã«ãã£ãŠçºçããããšãå€ãããã§ãããã«ããžèè «ãã¡ã«ã±ã«çްèãããåå®®é žããããã³å£è åœé ããïŒHPVé¢é£ïŒãè现èããïŒHBV/HCVé¢é£ïŒãªã©ã該åœãããããããè «çã¯éåžžãå ç«æå¶ç¶æ ãæ ¢æ§ççããããã¯ãã®äž¡æ¹ã®ç°å¢äžã§çºçããã
ãããã®ççš®ã®æ¥å¢ãç¹ã«åŸæ¥ã®å ç«æå¶ç¶æ ã«ãªã人ã ã«ãããå¢å ã¯ã宿䞻ãšãŠã€ã«ã¹ã®åè¡¡ã倱ãããå ç«ç·šéã®åŽ©å£ã瀺åããå¯èœæ§ããããæœäŒæ§HPVææã«å¯Ÿããå ç«å¶åŸ¡ã®äœäžã¯ãåå®®é žéšãå£è åœé ã«ãããçºçé²è¡ãå éããããããããªããåæ§ã«ã现èå·å®³æ§TçŽ°èæŽ»æ§ã®äœäžã¯ãç¡çç¶ã®ã¡ã«ã±ã«çްèçãã«ããžç å€ã®çºçŸã蚱容ããå¯èœæ§ãããã
çœè¡ç ããã³éªšé«ç°åœ¢æçå矀
ããã€ãã®æéçé¢é£ç ç©¶ã§ã¯ãã¯ã¯ãã³æ¥çš®åŸã«æ¥æ§çœè¡ç ããã³éªšé«ç°åœ¢æçå矀ïŒMDSïŒã®çäŸãå ±åãããŠããããããã®æªæ§è «çã¯ãççæ§ããã³å ç«èª¿ç¯ç°å¢ã«å¯ŸããŠéåžžã«ææã§ããã ãã§ãªããDNAã®å®å šæ§ã«åœ±é¿ãäžããç°å¢æé²ã«å¯ŸããŠãææã§ããããããã£ãŠãæç¶çãªå ç«æŽ»æ§åã®äžæãšããã«ç¶ãæå¶ããå 霢ãã骚é«ã«æ¢ã«ååšããåçœè¡ç æ§ã¯ããŒã³ã®æ¡å€§ãå éãããå¯èœæ§ã¯ååã«ããããŸããmRNAã¯ã¯ãã³ã«å«ãŸããDNAäžçŽç©ããç¹ã«éºäŒæ¯æ§ã¹ãã¬ã¹ã«ææãªé è¡åé§çްèã«åªå çã«çµã¿èŸŒãŸããå¯èœæ§ãèãããããçè«äžããããã®çްèã®è匱ãªã²ãã é åãžã®çµã¿èŸŒã¿ã¯çœè¡ç åãèªçºãããã
ãã®ãããªã¯ããŒã³åæ ã¯éå£ã¬ãã«ã§ã¯åŸ®çްãªå€åãããããªãããç¹ã«å¹Žéœ¢ãã¯ã¯ãã³æ¥çš®æŽãå ç«æŽ»æ§åããŒã«ãŒã§å±€å¥åãã瞊æç ç©¶ãéããŠæ€åºå¯èœãšãªãå¯èœæ§ãããã
æ»æçãŸãã¯ç°åžžãªåºåœ¢è «ç
æåŸã«ãmRNAã¯ã¯ãã³æ¥çš®ãšæéçã«è¿æ¥ããææã«ããŸããŸãã¯ç°åžžã«æªæ§åºŠã®é«ãåºåœ¢è «çãåºçŸããå¯èœæ§ãèãããããããã«ã¯é«æªæ§åºŠã°ãªãªãŒããèµèçãæ¥é墿®æ§èè «ãä¹³çãã®ä»ã®åºåœ¢è «çãå«ãŸããã
éå£ã¬ãã«ã§ã¯ãã¯ã¯ãã³æ¥çš®ãšçã®é¢é£æ§ã¯ãåºæºå€åŸåãšæ¯èŒããŠè¡æ¶²çïŒãªã³ãè «ãçœè¡ç ïŒããã³ãŠã€ã«ã¹é¢é£çã®äžåè¡¡ãªå¢å ãšããŠçŸããå¯èœæ§ãé«ããæ ¢æ§ççãT现èã®æ¶èãåå ã§ããå Žåãã¯ã¯ãã³æ¥çš®åŸçæéã§æ©æçºççã®å¢å ããããã¯æ¥éã«é²è¡ããçãæ²»çæµææ§çã®ã¯ã©ã¹ã¿ãŒã芳å¯ãããããšãäºæ³ããããå ç«ç£èŠæ©èœãéåããããççæ§ãµã€ãã«ã€ã³ãé質埮å°ç°å¢ãå€åãããããããšãäŒç ç¶æ ã®æœåšæ§çãäžç®å çããŸãã¯åŸ®å°è»¢ç§»ã掻æ§åãããå¯èœæ§ãããããããã¯ã¯ã¯ãã³æ¥çš®åŸ12ïœ36ã¶æä»¥å ã«å®¹æã«çºçŸãããã
çµè«
ãããã®ãã¿ãŒã³ã¯ããããå æé¢ä¿ã蚌æãããã®ã§ã¯ãªãããåãªãå¶ç¶ãšããŠçä»ããã¹ãã§ããªããã¿ãã³ãã¢ã¹ãã¹ããå åæ³ããä¹±ç©è³ªãªã©ä»ã®ç°å¢æé²ãçãšã®é¢é£æ§ãææãããŠãããåœåã®èŠåã¯æççã«åãæ¢ãããããããããã®äºäŸã«ãããŠãå³å¯ãªç ç©¶ã芳å¯ãå®éšçç ç©¶ã«ãã£ãŠå æé¢ä¿ãå®èšŒããããåæ§ã®ååãããã«ãé©çšãããã¹ãã§ãããç ç©¶è ã¯ãæ€é²ãå人çã»è·æ¥çãªå ±åŸ©ããè§£æŸããããããã®åæãåçŸãæ¡å€§ããæš©éãäžããããªããã°ãªããªãã
COVID-19ã¯ã¯ãã³æ¥çš®ãšããçºçãé¢é£ä»ããå ±åãå¢å ããŠããçŸç¶ãçè§£ãããããã®é¢é£æ§ãçã®å æé¢ä¿ãåæ ããŠãããã©ããã倿ããããã«ã¯ãããããæœåšçãªã¡ã«ããºã ã®è©äŸ¡ãšå®éåãç ç©¶ã®åªå 課é¡ãšãªãå¿ èŠãããã
ç¹å®ã®ããçš®ãç¹ã«çšãªãŸãã¯äŸµæ»æ§ã®äºåããæªæ¥çš®è ãšæ¯èŒããŠæ¥çš®è ã«ãããŠããé »ç¹ã«çºçãããã©ãããæããã«ããã«ã¯ãé·æã«ãããéå£ã¬ãã«ã®ç ç©¶ãäžå¯æ¬ ã§ããããã®ãããå ¬è¡è¡çã®èгç¹ãããç§åŠã³ãã¥ããã£ãšèŠå¶åœå±ããããã®çåã«å¯Ÿããå³å¯ã§åãã®ãªã調æ»ã«åãçµãããšã極ããŠéèŠã§ããã